Literature DB >> 18098283

The molecular etiology of breast cancer: evidence from biomarkers of risk.

Nilesh W Gaikwad1, Li Yang, Paola Muti, Jane L Meza, Sandhya Pruthi, James N Ingle, Eleanor G Rogan, Ercole L Cavalieri.   

Abstract

Estrogens can become endogenous carcinogens via formation of catechol estrogen quinones, which react with DNA to form specific depurinating estrogen-DNA adducts. The mutations resulting from these adducts can lead to cell transformation and the initiation of breast cancer. Estrogen metabolites, conjugates and depurinating DNA adducts in urine samples from 46 healthy control women, 12 high-risk women and 17 women with breast cancer were analyzed. The estrogen metabolites, conjugates and depurinating DNA adducts were identified and quantified by using ultraperformance liquid chromatography/tandem mass spectrometry. The levels of the ratios of depurinating DNA adducts to their respective estrogen metabolites and conjugates were significantly higher in high-risk women (p < 0.001) and women with breast cancer (p < 0.001) than in control subjects. The high-risk and breast cancer groups were not significantly different (p = 0.62). After adjusting for patient characteristics, these ratios were still significantly associated with health status. Thus, the depurinating estrogen-DNA adducts are possible biomarkers for early detection of breast cancer risk and response to preventive treatment. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18098283      PMCID: PMC4422386          DOI: 10.1002/ijc.23329

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity.

Authors:  Muhammad Zahid; Ekta Kohli; Muhammad Saeed; Eleanor Rogan; Ercole Cavalieri
Journal:  Chem Res Toxicol       Date:  2006-01       Impact factor: 3.739

Review 2.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

3.  Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Rudolf Kaaks; Franco Berrino; Timothy Key; Sabina Rinaldi; Laure Dossus; Carine Biessy; Giorgio Secreto; Pilar Amiano; Sheila Bingham; Heiner Boeing; H Bas Bueno de Mesquita; Jenny Chang-Claude; Françoise Clavel-Chapelon; Agnès Fournier; Carla H van Gils; Carlos A Gonzalez; Aurelio Barricarte Gurrea; Elena Critselis; Kay Tee Khaw; Vittorio Krogh; Petra H Lahmann; Gabriele Nagel; Anja Olsen; N Charlotte Onland-Moret; Kim Overvad; Domenico Palli; Salvatore Panico; Petra Peeters; J Ramón Quirós; Andrew Roddam; Anne Thiebaut; Anne Tjønneland; Ma Dolores Chirlaque; Antonia Trichopoulou; Dimitrios Trichopoulos; Rosario Tumino; Paolo Vineis; Teresa Norat; Pietro Ferrari; Nadia Slimani; Elio Riboli
Journal:  J Natl Cancer Inst       Date:  2005-05-18       Impact factor: 13.506

4.  Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens.

Authors:  R R Newbold; J G Liehr
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

5.  Imbalance of estrogen homeostasis in kidney and liver of hamsters treated with estradiol: implications for estrogen-induced initiation of renal tumors.

Authors:  E L Cavalieri; S Kumar; R Todorovic; S Higginbotham; A F Badawi; E G Rogan
Journal:  Chem Res Toxicol       Date:  2001-08       Impact factor: 3.739

6.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.

Authors:  T Key; P Appleby; I Barnes; G Reeves
Journal:  J Natl Cancer Inst       Date:  2002-04-17       Impact factor: 13.506

7.  Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol.

Authors:  Muhammad Saeed; Eleanor Rogan; Sandra V Fernandez; Fathima Sheriff; Jose Russo; Ercole Cavalieri
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

8.  Synthesis and structure elucidation of estrogen quinones conjugated with cysteine, N-acetylcysteine, and glutathione.

Authors:  K Cao; D E Stack; R Ramanathan; M L Gross; E G Rogan; E L Cavalieri
Journal:  Chem Res Toxicol       Date:  1998-08       Impact factor: 3.739

9.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1.

Authors:  C L Hayes; D C Spink; B C Spink; J Q Cao; N J Walker; T R Sutter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

Review 10.  Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.

Authors:  W Yue; R J Santen; J-P Wang; Y Li; M F Verderame; W P Bocchinfuso; K S Korach; P Devanesan; R Todorovic; E G Rogan; E L Cavalieri
Journal:  J Steroid Biochem Mol Biol       Date:  2003-09       Impact factor: 4.292

View more
  54 in total

1.  Mechanism of DNA depurination by carcinogens in relation to cancer initiation.

Authors:  Ercole Cavalieri; Muhammad Saeed; Muhammad Zahid; David Cassada; Daniel Snow; Momcilo Miljkovic; Eleanor Rogan
Journal:  IUBMB Life       Date:  2011-12-09       Impact factor: 3.885

2.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

3.  Induction of NAD(P)H-quinone oxidoreductase 1 by antioxidants in female ACI rats is associated with decrease in oxidative DNA damage and inhibition of estrogen-induced breast cancer.

Authors:  Bhupendra Singh; Nimee K Bhat; Hari K Bhat
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

4.  Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland.

Authors:  Taehyun Kim; Hoyong Park; Wei Yue; Ji-Ping Wang; Kristen A Atkins; Zhenguo Zhang; Eleanor G Rogan; Ercole L Cavalieri; Khalid S Mohammad; Sanghee Kim; Richard J Santen; Sarah E Aiyar
Journal:  Breast Cancer Res Treat       Date:  2010-12-18       Impact factor: 4.872

5.  Redox cycling of catechol estrogens generating apurinic/apyrimidinic sites and 8-oxo-deoxyguanosine via reactive oxygen species differentiates equine and human estrogens.

Authors:  Zhican Wang; Esala R Chandrasena; Yang Yuan; Kuan-wei Peng; Richard B van Breemen; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2010-08-16       Impact factor: 3.739

Review 6.  The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity.

Authors:  Ercole Cavalieri; Eleanor Rogan
Journal:  Mol Aspects Med       Date:  2013-08-30

7.  Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts.

Authors:  Nilesh W Gaikwad; William J Bodell
Journal:  Free Radic Biol Med       Date:  2011-10-18       Impact factor: 7.376

8.  Estrogen carcinogenesis: specific identification of estrogen-modified nucleobase in breast tissue from women.

Authors:  Qiang Zhang; Rebecca L Aft; Michael L Gross
Journal:  Chem Res Toxicol       Date:  2008-08-02       Impact factor: 3.739

9.  N-acetylcysteine blocks formation of cancer-initiating estrogen-DNA adducts in cells.

Authors:  Muhammad Zahid; Muhammad Saeed; Mohammed F Ali; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Free Radic Biol Med       Date:  2010-05-31       Impact factor: 7.376

10.  Novel biomarkers for risk of prostate cancer: results from a case-control study.

Authors:  Li Yang; Nilesh W Gaikwad; Jane Meza; Ercole L Cavalieri; Paola Muti; Bruce Trock; Eleanor G Rogan
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.